DUBLIN, Ireland, Nov. 22, 2021 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, announced today that Greg Divis, Chief Executive Officer of Avadel, will participate in the following upcoming investor conferences:
A webcast of these events, as well as archived recordings, will be available on Avadel’s Investor Relations website, investors.avadel.com, for 90 days following each conference.
About Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (Nasdaq: AVDL) is a biopharmaceutical company focused on transforming medicines to transform lives. Our approach includes applying innovative solutions to the development of medications that address the challenges patients face with current treatment options. Our current lead drug candidate, FT218, is an investigational formulation of sodium oxybate leveraging our proprietary drug delivery technology and designed to be taken once at bedtime for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. For more information, please visit www.avadel.com.
Investor Contact:
Courtney Turiano
Stern Investor Relations, Inc.
Courtney.Turiano@sternir.com
(212) 698-8687
Media Contact:
Nicole Raisch Goelz
Real Chemistry
ngoelz@realchemistry.com
(408) 568-4292
Proposed business combination to create a North American technology company with an AI-driven fintech marketplace.…
NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Chronic pain affects millions of…
Oakville, Ontario--(Newsfile Corp. - March 25, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF)…
Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30…
VANCOUVER, BC / ACCESSWIRE / March 25, 2024 / Bruush Oral Care Inc. (NASDAQ:BRSH) (the…
ORLANDO, FL / ACCESSWIRE / March 25, 2024 / Black Book Research, the premier source…